Teplizumab Approval Drives 90% Surge in Type 1 Diabetes Autoantibody Screening
FDA approval of the first T1D delay drug nearly doubled islet autoantibody testing, but critical gaps remain in screening healthy children.
Summary
After teplizumab became the first FDA-approved drug to delay type 1 diabetes onset, clinicians nearly doubled their ordering of islet autoantibody tests. A study of over 28,000 nondiabetic patients compared testing patterns before and after approval, finding the biggest increases among adults and children with early blood sugar abnormalities. Providers also shifted toward ordering more comprehensive antibody panels, in line with clinical guidelines. However, screening of normoglycemic children — arguably the highest-priority group for early intervention — remained surprisingly low, mostly handled by primary care doctors ordering only one to three tests per year. The findings suggest that while drug approval catalyzed real-world change, systematic screening programs are still needed to catch at-risk individuals before symptoms appear.
Detailed Summary
Type 1 diabetes (T1D) does not appear overnight — it follows a predictable autoimmune progression that can be detected years before symptoms emerge using islet autoantibody testing. The 2022 FDA approval of teplizumab, which delays T1D onset by approximately two years in high-risk individuals, created a new clinical imperative: identify at-risk patients early enough to intervene.
Researchers from Quest Diagnostics and Indiana University analyzed real-world autoantibody ordering data from 28,206 nondiabetic individuals across two one-year windows — before approval (November 2017–2018) and after approval (November 2022–2023). They tracked which antibody panels were ordered, who ordered them, and how results differed between age groups and glycemic status.
Islet autoantibody testing increased 1.9-fold in the post-approval period, a statistically significant rise compared to other laboratory testing trends. Adults drove much of this growth, and testing also increased among children who already showed dysglycemia. Clinicians moved toward ordering more complete panels — three or four antibodies rather than one or two — reflecting better alignment with screening guidelines. Among dysglycemic children tested post-approval, multiple antibody positivity was 35.6% higher than expected, suggesting improved case detection in a genuinely at-risk group.
Despite this progress, important gaps remain. Screening of normoglycemic children — the group that would benefit most from teplizumab if identified early — remains limited and is largely driven by primary care providers ordering just one to three tests per year. Endocrinologists handled most dysglycemic cases, while general practitioners managed normoglycemic screening, a division that may limit systematic identification of at-risk children.
These findings underscore that drug approval alone is insufficient to achieve population-level early detection. Integrating autoantibody screening into routine pediatric care pathways, similar to newborn screening programs, will be essential to fully realize the preventive potential of teplizumab and future T1D therapies.
Key Findings
- Islet autoantibody testing increased 1.9-fold after teplizumab FDA approval, significantly outpacing other lab test growth.
- Multiple antibody positivity in dysglycemic children was 35.6% higher post-approval, indicating better detection of high-risk cases.
- Providers shifted toward ordering complete 3–4 antibody panels, improving alignment with clinical screening guidelines.
- Over 80% of orders came from providers testing just 1–3 patients per year, revealing highly fragmented, low-volume screening.
- Screening of normoglycemic children by primary care providers remains critically low despite being the key target population.
Methodology
Retrospective analysis of Quest Diagnostics laboratory data comparing 28,206 nondiabetic individuals (HbA1c <6.5%) tested in two matched one-year windows before and after teplizumab approval. Participants were stratified by age (<20 vs ≥20 years) and glycemic status (normoglycemic vs dysglycemic). Statistical comparisons assessed changes in testing volume, panel completeness, provider type, and antibody positivity rates.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, limiting assessment of confounding variables, patient demographics, and statistical methodology. The study relies on a single large commercial laboratory's data (Quest Diagnostics), which may not represent all US clinical settings or uninsured populations. Pre- and post-approval periods are separated by four years, so temporal trends unrelated to teplizumab may contribute to observed differences.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.